Does PCOS Affect Egg Quality? What AMH Doesn't Tell You

Does PCOS Affect Egg Quality?

Not in the way most people assume. A 2015 prospective study directly compared oocyte quality between 97 women with polycystic ovarian morphology and 97 age-matched controls undergoing their first ICSI cycle for male-factor infertility, assessing 1,013 oocytes against 774 controls. The rate of mature (metaphase II) oocytes and the rate of morphologically abnormal oocytes were equivalent between the two groups — and the polycystic-ovary group went on to significantly higher implantation and clinical pregnancy rates, not lower ones. The study’s own conclusion is direct: polycystic ovarian morphology did not have a negative impact on oocyte or embryo quality, or on IVF outcome.

That is one well-designed study, not the final word on every phenotype of PCOS, but it lands on the same conclusion as the wider literature on egg quantity versus quality, which this page answers together because they are the same underlying question asked two different ways — along with what an IVF egg retrieval actually looks like in PCOS, covered further down. Egg quality is one specific piece of the complete PCOS fertility guide, separate from whether conception happens at all.

You may see PCOS written as polyendocrine metabolic ovarian syndrome (PMOS), after a 2026 global consensus of more than 50 organisations renamed it. Every figure on this page applies under either name — only the label changed.

Egg Quantity vs Egg Quality: The Distinction That Actually Matters

PCOS ovaries reliably produce more eggs per retrieval, and that is the mechanism behind the diagnosis itself — a higher resting pool of small antral follicles is one of the diagnostic features of polycystic ovarian morphology. A 2006 meta-analysis pooling nine studies, 458 women with PCOS against 694 matched controls undergoing conventional IVF, found PCOS patients had significantly more oocytes retrieved per collection — a weighted mean difference of 3.4 additional oocytes — but a significantly reduced chance of reaching oocyte retrieval at all per started cycle (OR 0.5, 95% CI 0.2–1.0), reflecting a higher cycle-cancellation rate to manage over-response. Fertilisation rate showed no significant difference, and critically, clinical pregnancy rate per started cycle was statistically identical between the groups (OR 1.0, 95% CI 0.8–1.3).

More eggs, more cancelled cycles to manage the response safely, and the same odds of a clinical pregnancy once a cycle proceeds — that is a quantity story with a safety-management complication, not a quality story.

The mechanism behind that split is about which stage of follicle development gets stuck, not about the eggs themselves being damaged. In a typical cycle, a cohort of small follicles is recruited each month and almost all of them are lost to a normal process called atresia, leaving one dominant follicle to ovulate. In PCOS, disrupted FSH signalling and higher circulating androgens interrupt that selection process earlier, so more small antral follicles survive and accumulate instead of being cleared — which is why an ultrasound or an AMH test finds more of them sitting there, and why a stimulated IVF cycle recruits more of them at once. That is an arrest in follicle selection, not documented evidence of damage to the oocytes riding inside those follicles, which is consistent with why quality markers measured directly on the retrieved eggs above came back equivalent, not worse.

What AMH Actually Measures — and What It Does Not Tell You

AMH is elevated in PCOS because it is a direct byproduct of having more small antral follicles, not because it reflects anything about the eggs those follicles contain. A 2011 diagnostic study of 240 patients set the current AMH threshold for polycystic ovarian morphology at 35 pmol/L, or 5 ng/mL, chosen specifically because it distinguished ovarian appearance, at 92% sensitivity and 97% specificity — a diagnostic marker for morphology, not a quality assay for the oocytes inside those follicles.

A separate meta-analysis of AMH’s actual predictive power found it does one thing very well: AMH and antral follicle count predicted an excessive ovarian response to stimulation with 82% sensitivity and 76% specificity, which is genuinely useful for a clinic planning a stimulation dose to avoid over-response. Nothing in that meta-analysis, or in the diagnostic literature that established AMH’s PCOS threshold, measured or claimed to measure egg quality. A high AMH means “expect more follicles to respond” — it does not mean “expect worse eggs.” The 2023 international PCOS guideline is the current standard that formally recognises an elevated AMH as an alternative to a follicle count on ultrasound for diagnosing polycystic ovarian morphology — but in adults only. The guideline withholds that alternative for adolescents, who are still assessed by ultrasound and clinical/biochemical criteria alone. That diagnostic role, either way, is a different use of the same number than a fertility or quality forecast.

PCOS and IVF Egg Retrieval: More Eggs, More OHSS Risk, Similar Live Birth Rate

The real, well-documented risk in a PCOS IVF cycle is ovarian hyperstimulation syndrome (OHSS), not poor egg quality. A prospective cohort of 290 women under 37 undergoing their first IVF cycle, grouped by ovarian appearance, found severe OHSS requiring hospitalisation in 15.4% of women with PCOS and 12.6% of women with polycystic ovaries without the full syndrome, against 2.7% in women with normal ovaries — while live birth rates per cycle started were statistically similar across all three groups: 37% (PCOS), 38% (PCO) and 40% (normal ovaries). The same trade-off shows up again in PCOS egg freezing retrieval cycles specifically, which pull more eggs per cycle at a proportionally higher OHSS risk.

That is the pattern this page keeps returning to from a different angle each time: PCOS ovaries do something mechanically different during stimulation — recruit more follicles, respond more strongly, carry a real and higher risk of over-response — without that translating into a lower chance of a live birth once a cycle reaches transfer. Coasting, lower-dose stimulation protocols, and an antagonist trigger instead of hCG are standard techniques a fertility clinic uses specifically to manage this over-response risk in PCOS, discussed further with a clinician planning a specific protocol rather than decided from population data alone.

Does PCOS Phenotype Change the Egg-Quality Picture?

None of the studies above sorted their PCOS or PCOM groups by phenotype, and that is a real, honest gap rather than a settled non-issue. The insulin-resistant pattern carries measurably higher circulating insulin, which independently drives ovarian androgen production, and it is biologically plausible that heavier androgen exposure inside the follicle affects oocyte competence differently than in a lean, lower-insulin presentation. Plausible is not the same as demonstrated: no trial in the oocyte-quality literature above has actually tested that split, so the honest answer is that the “quantity, not quality” finding is the best evidence available for PCOS broadly, not a guarantee that holds identically across every phenotype. Lean PCOS carries a different metabolic profile again, and the same caveat applies there in the opposite direction — an absence of evidence of a phenotype-specific quality problem, not evidence that one has been ruled out.

Who This Does Not Apply To — the Limits of “Quantity, Not Quality”

This page’s evidence base is not a blanket reassurance for every situation egg quality gets raised in.

• Age still matters exactly as much. Nothing above changes the basic biology of oocyte aneuploidy rising with age. A 25-year-old and a 40-year-old with the same PCOS diagnosis are not working from the same egg-quality starting point, and PCOS does not cancel out that separate, age-driven decline — what changes specifically after 35 is broken down here.
• The evidence above is largely PCOS-defined-by-morphology, not every phenotype. Lean PCOS carries a different metabolic profile than the insulin-resistant pattern, and no trial has broken oocyte-quality findings down by phenotype specifically.
• This is not evidence that IVF is risk-free in PCOS. The OHSS numbers above are real and are the reason IVF in PCOS is managed with specific protocols, not the standard approach applied without adjustment.
• A high AMH is not, on its own, a PCOS diagnosis or a fertility prognosis. What the number means and what it does not diagnose is covered in full here.
• Supplement marketing for “egg quality” is a separate claim from anything measured above. CoQ10 is the most heavily marketed example, and the trial evidence behind it comes from women with diminished ovarian reserve, not PCOS — matching CoQ10 brands to the trial dose checks specific products against what those trials actually used.

If a miscarriage, rather than egg quality, is the actual worry behind this search, that has its own separate evidence base and is covered in full here — the two questions get confused often, and they are not the same evidence. And if conception itself, rather than what happens during IVF specifically, is the open question, the actual conception rates are covered here.